Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Frustration Over English Funding Rejection For Zytiga And A Win For Ledaga

Zyntiga Decision 'Highlights Need For Innovative Pricing Models'

Executive Summary

Janssen and UK health technology assessment body NICE are being urged to sit down together and agree a suitable price for using Zytiga as a first-line treatment for advanced prostate cancer.

You may also be interested in...

Astellas Pips Janssen To Post With English Funding For New Prostate Cancer Indication

NICE’s decision today affirming the cost effectiveness of Astellas Pharma’s Xtandi for hormone-sensitive metastatic prostate cancer contrasts with the health technology assessment body’s guidance last month for Janssen’s Erleada.

No English Funding For Lymphoma Drugs Ledaga and Poteligeo

Limitations in the design of the clinical trials that were carried out for each drug are among the concerns highlighted by the health technology assessment body in two interim guidances that are now out for consultation.

Academic Study Confounds Latest UK Zytiga Reimbursement Consultation

Janssen, the Institute of Cancer Research and patient groups have reacted with disappointment to NICE draft guidance recommending that Zytiga should not be funded by England's National Health Service in a subset of prostate cancer patients. But the existence of an academic study has complicated the situation in an unusual way, and Janssen still hopes to steer a path to reimbursement.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts